Article
The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
European journal of pharmacology - 5 Sept 2017
Chistiakov Dimitry A, Chekhonin Ivan V, Chekhonin Vladimir P
Abstract excerpt
In epithelial tumors, the epidermal growth factor receptor (EGFR) controls key signaling pathways responsible for growth, proliferation, migration, and survival of tumor cells. The epidermal growth factor receptor variant III (EGFRvIII) is the most common EGFR mutation that occurs in up to 30% of high-grade gliomas especially glioblastoma multiforme (GBM). EGFRvIII arises from the deletion of exon 2-7 that leads...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.